WO1996027018A1 - Plasmide pour l'expression de proteines de recombinaison modifiees dans un systeme bacterien - Google Patents

Plasmide pour l'expression de proteines de recombinaison modifiees dans un systeme bacterien Download PDF

Info

Publication number
WO1996027018A1
WO1996027018A1 PCT/US1996/002866 US9602866W WO9627018A1 WO 1996027018 A1 WO1996027018 A1 WO 1996027018A1 US 9602866 W US9602866 W US 9602866W WO 9627018 A1 WO9627018 A1 WO 9627018A1
Authority
WO
WIPO (PCT)
Prior art keywords
casein
human
plasmid
recombinant
protein
Prior art date
Application number
PCT/US1996/002866
Other languages
English (en)
Inventor
Pradip Mukerji
Jennifer Marie Thurmond
Lennart Hansson
Jeffrey Harris Baxter
Robert George Hards
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/554,137 external-priority patent/US5942254A/en
Priority claimed from US08/554,642 external-priority patent/US5710044A/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to NZ303621A priority Critical patent/NZ303621A/en
Priority to JP8526438A priority patent/JPH11500920A/ja
Priority to EP96906664A priority patent/EP0812362A1/fr
Publication of WO1996027018A1 publication Critical patent/WO1996027018A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732—Casein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Definitions

  • This invention relates to a novel method for producing modified recombinant proteins in a bacterial system.
  • the method comprises preparing a single vector having a nucleotide sequence encoding an exogenous protein and an enzyme capable of modifying the protein in vivo, and expressing the vector in the host cell to produce a modified protein.
  • An aspect of the invention relates to a single vector containing a promoter, followed by a protein encoding sequence, followed by an enzyme encoding sequence. Data are presented that show that the modified protein has the same bioactivity as the native human protein.
  • human milk is the best nutritional source for human infants. Human milk is not only an ideal source of nutrients for the developing infant, but also contains both immunoglobulins and non-immunological factors that protect the infant from infection by various organisms. Human milk is also easily digested by the infant and is less likely to cause allergic reactions than is infant formula based on bovine milk.
  • Human milk differs from bovine milk as well as the milk of other mammalian species in various ways.
  • Bovine milk contains 2 ⁇ -caseins plus ⁇ - and K-casein, but human milk contains only ⁇ - and K-casein. Additionally, the amino acid sequences of human milk protein differ from that of other mammalian milk proteins.
  • casein In addition to being a source of amino acids necessary for the synthesis of proteins required for the growth and development of infants, human milk is recognized as containing proteins, including casein, that have other important biological functions .
  • ⁇ - casein is one of the most abundant milk proteins synthesized in the mammary gland. After post-translational modification in the Golgi apparatus, it is excreted as large calcium-dependent aggregates called micelles.
  • ⁇ -casein is not a single entity, but is a heterogeneous group of phosphoproteins secreted during lactation in response to lactogenic hormones.
  • human ⁇ —casein The primary structure of human ⁇ —casein was determined by Greenberg et al . (Journal of Biological Chemistry 259:5132-5138, 1984) . It was shown to be a phosphorylated protein with phosphorylation sites at specific seryl and threonyl residues located near the amino terminus. Comparison of human and bovine ⁇ - caseins showed 47% identity. The sequence of human
  • K-casein was determined by Brignon et al. (Federation of
  • Human casein consists largely (>80%) of the ⁇ -form with a smaller amount in the K-form (Greenberg et al. , 1984) .
  • Native ⁇ -casein is a 25 kDa protein.
  • ⁇ -casein molecules show variable degrees of post-translational phosphorylation ranging from zero to five phosphate groups per polypeptide chain (Greenberg et al . , 1984; Hansson et al . , Protein Expression and Purification 4:373-381, 1993) .
  • Phosphate groups in the native protein are attached to serine and threonine residues located near the amino terminus (Greenberg et al. , 1984) .
  • E. coli eukaryotic proteins produced in E. coli lack the specific post-translational modifications which may occur within the eukaryotic cell, such as glycosylation, phosphorylation, acetylation, or amidation.
  • One vector has a nucleotide sequence encoding an exogenous protein that is capable of being phosphorylated by the catalytic domain of a protein kinase.
  • the other vector has a nucleotide sequence encoding the protein kinase catalytic domain. Both vectors are introduced into E. coli and production of the exogenous protein and the protein kinase catalytic domain is induced so that the exogenous protein is phosphorylated. The bacterial cells are then lysed and the exogenous phosphorylated protein is isolated using standard isolation techniques.
  • CA No. 2,083,521 does not suggest or disclose the method of the instant invention.
  • the present invention provides a single vector expressing both the substrate and the kinase enzyme.
  • the method of Pawson et al . requires the use of two vectors.
  • the expression system disclosed herein results in specific phosphorylation of the exogenous protein as determined by antibody to phosphoserine, while the expression system of Pawson et al . results in non-specific phosphorylation of both host proteins and exogenous proteins. This would adversely affect the growth of host bacteria in scale-up efforts for industrial applications.
  • the present invention unlike that of Pawson et al. , provides for high level production of a phosphorylated, recombinant protein suitable for commercial production.
  • Simcox et al. Strategies in molecular biology 7(3) :68-69 (1994) constructed two E. coli strains that harbor a tyrosine kinase plasmid. These TK (tyrosine kinase) strains can be used for generating phosphorylated proteins when transformed with a plasmid containing sequences encoding a phosphorylation target domain or protein. Both E. coli strains carry an inducible tyrosine kinase gene. One strain, TKB1, is useful for expressing genes whose expression is directed by the T7 promoter. The system developed by Simcox et al .
  • tyrosine kinase-containing plasmid differs from the present invention in that it requires two constructs, i.e., a tyrosine kinase-containing plasmid and a plasmid vector containing a gene encoding a protein or domain to be phosphorylated.
  • Hansson et al demonstrated that recombinant human ⁇ - casein was expressed in the yeast, S . cerevisiae, using the pYES 2.0 vector (Invitrogen Corp., San Diego, CA) . Production levels were estimated to be approximately 10% of the production found in E. coli .
  • recombinant ⁇ -casein obtained from S . cerevisiae a eukaryotic cell that has endogenous enzymes capable of phosphorylating proteins, was phosphorylated, but the protein produced by E. coli , a prokaryotic cell that lacks the ability in its native state to phosphorylate, was non-phosphorylated.
  • recombinant human casein kinase II (rhCKII) produced in and purified from E. coli can phosphorylate protein substrates in vi tro (Shi et al. , Proceeding of the National Academy of Sciences, USA 91:2767-2771, 1994) .
  • One specific embodiment of the present invention uses a nucleotide sequence encoding a recombinant human casein kinase II in a single construct with nucleotide sequence encoding ⁇ -casein to transform E. coli and produce phosphorylated ⁇ -casein.
  • exogenous proteins capable of being modified through the process of the present invention include but are not limited to human caseins, including ⁇ -casein, cell receptor proteins, fatty acylated proteins including palmitoylated proteins, mammalian muscle proteins, the gag polyproteins of retroviruses, and mammalian proteins targeted by retroviral src kinases.
  • Transmembrane glycoproteins that acquire covalent palmitate after synthesis include the insulin, ⁇ 2 -adrenergic and transferrin receptors.
  • Proteins that function as cell surface receptors, tyrosine and serine/threonine kinases, their substrates, a phosphatase, G-proteins, and Ca2+ are known to be fatty acylated.
  • Representative of enzymes useful in the present invention because of their capacity to transfer functional groups to specific exogenous proteins in a host cell include but are not limited to kinases, such as tyrosine kinases or casein kinase, transferases, such as mammalian and yeast palmitoyl transferases, and kinases coded for by the src gene of retroviruses.
  • promoters useful in the present invention include inducible promoters such as T7, ⁇ P L , ⁇ P R , and Tac and constitutive promoters such as bla and spa .
  • host cells capable of being transformed and then expressing the modified proteins include but are not limited to the bacterial cells E. coli K-12 and E. coli B, Bacillus species, Lactohacillus species, and Streptococcus species and eukaryotic cells such as yeast cells or mammalian cells.
  • exogenous protein is one that originates outside the organism that is producing it.
  • the term is sometimes used in the relevant DNA cloning literature also to refer to the recombinant protein produced by the transformed recipient organism.
  • an exogenous protein produced using DNA cloning techniques may be referred to as a recombinant protein.
  • the terms will be used interchangeably herein since the distinction is frequently not made in the literature.
  • the word "recombinant” will be used to refer to the protein produced by the transformed organism, and "exogenous” will be used when referring to the native, non-recombinant protein or nucleotide sequence encoding the protein.
  • What is disclosed herein is a method for producing a modified recombinant protein in a host cell comprising the steps of preparing a single vector having a promoter sequence, an exogenous protein sequence, and a nucleotide sequence encoding an enzyme capable of modifying the exogenous protein; transforming the host cell with the vector; expressing the vector in the host cell whereby the produced enzyme modifies the produced recombinant protein; and isolating the produced, modified recombinant protein.
  • Also disclosed herein in a more specific embodiment of the invention is a method for producing a phosphorylated recombinant protein in a host cell comprising the steps of preparing a single vector having a promoter sequence followed by a nucleotide sequence encoding an exogenous protein capable of being phosphorylated by a protein kinase, followed by a nucleotide sequence encoding a protein kinase capable of phosphorylating the exogenous protein; transforming the host cell with the vector; expressing the vector in the host cell whereby the produced protein kinase phosphorylates the produced recombinant protein; and isolating the phosphorylated protein.
  • the present invention provides a novel method for producing a modified recombinant human protein in bacterial expression systems wherein the resulting recombinant human protein has utility for the inhibition of attachment of H. influenzae to human cells and in the prevention and treatment of otitis media in human infants.
  • Using a combination of two human casein kinase encoding sequences, expressing respectively the alpha and beta subunits of the kinase they demonstrated the in vivo production of recombinant phosphorylated human ⁇ -casein in E. coli .
  • the sequence coding for human casein kinase II was placed in tandem with the sequence coding for ⁇ -casein with the result that a significant portion of the recombinant ⁇ -casein produced in E. coli was phosphorylated as in human milk.
  • the method of the present invention can also be used for in vivo specific glycosylation, amidation, or acetylation of recombinant proteins in transformed host cells or for the transfer of fatty acids to appropriate recombinant protein substrates in transformed host cells.
  • hCKII ⁇ is co-expressed in a single construct with a nucleotide sequence encoding a human ⁇ -casein in a bacterial expression system to achieve efficient in vivo phosphorylation of the appropriate serine and threonine residues of recombinant human ⁇ -casein.
  • a nucleotide sequence encoding hCKII ⁇ and a nucleotide sequence encoding human ⁇ —casein were co-expressed in E. coli using a single inducible expression vector demonstrated the ability of recombinant hCKII ⁇ to phosphorylate recombinant ⁇ - casein in vivo .
  • Phosphorylated ⁇ -casein produced using the method of the invention is demonstrated to have the same bioactivity as native human ⁇ -casein as shown by its ability to inhibit adhesion of H. influenzae to human pharyngeal cells.
  • Figure 1 shows physical maps of expression vectors pS637 and pRJB-6 constructed for inducible intracellular expression in E. coli . 191 base pairs were removed from pS637 to produce PRJB-6.
  • Figure 2 shows physical maps of expression vectors pRJB-6 and pRJB-9 and illustrates how pRJB-6 was cut and ligated to CKII ⁇ to form pRJB-9.
  • Figure 3 shows physical maps of expression vectors pS637 and pRJB-7 and shows how pS637 was cut and ligated to CKII ⁇ to form pRJB-7.
  • pRJB-7 has T7 promoters in front of both the ⁇ -casein and casein kinase genes.
  • Figure 4 shows the physical map of expression vector pS750, constructed for inducible expression and to mediate production of intracellularly localized protein in E. coli .
  • Figure 5 shows SDS-PAGE of Met- ⁇ -casein produced in
  • Lane 1 molecular weight marker (Bio-Rad prestained, relative molecular weights 106, 80, 49.5, 32.5, 27.5, 18.5 kDa) ;
  • lane 2 non-phosphorylated recombinant ⁇ -casein;
  • lane 3 5P- ⁇ -casein;
  • lane 4 pS750 induced with IPTG in BL2KDE3);
  • lane 5 pS750/pET-lld-CKII ⁇ induced with IPTG in BL2KDE3);
  • lane 6 pS750 induced with IPTG in BL21(DE3)pLysS; lane 1 -.
  • Lane 1 native ⁇ -casein with five attached phosphate groups (5P- ⁇ - casein) ; lane 2: pS750/pET-lld-CKII ⁇ induced with IPTG in BL21 (DE3)pLysE cells; lane 3: pS750 induced with IPTG in BL21 (DE3)pLysE; lane 4: pS750/pET-lld- CKII ⁇ induced with IPTG in BL21 (DE3)pLysS; lane 5: pS750 induced with IPTG in BL21 (DE3)pLysS; lane 6: pS750/pET-lld- CKII ⁇ induced with IPTG in BL2KDE3); lane 7: pS750 induced with IPTG in BL2KDE3); lane 8: 5P- ⁇ -casein; lane 9: non-phosphorylated recombinant ⁇ - casein; lane 10: molecular weight marker (Bio-R
  • Figure 7 shows SDS-PAGE of Met- ⁇ -casein produced in
  • E. coli HMS174 (DE3)pLysS stained with Ethyl Stains-All using the vectors pS750 and pET-lld- CKII ⁇ .
  • Lane 1 molecular weight marker (Bio Rad prestained); lane 2: pS750 uninduced; lane 3: pS750 induced with IPTG; lane
  • Lane 1 molecular weight marker (Gibco BRL, relative molecular weights 43.1, 29.2, 18.8, 16.5, 6.4 kDa); lane 2: 50 ng native human ⁇ -casein; lane 3: uninduced HMS174 (DE3 )pLysS (pRJB-7) ; lane 4: induced HMS174 (DE3)pLysS (pRJB-7) ; lane 5: uninduced HMS174 (DE3 )pLysS (pET-lld-CKII ⁇ ) ; lane 6: induced HMS174 (DE3)pLysS (pET-lld-CKII ⁇ ) ; lane 7: uninduced HMS174 (DE3)pLysS (pRJB-9) ; lane 8: induced HMS174(DE3)pLysS(pRJB-9) .
  • Figure 9 shows a Western immunoblot analysis with antibody to phosphoserine. Lane 1: low molecular weight
  • lane 2 1 ⁇ g native human ⁇ - casein
  • lane 3 2 ⁇ g native human ⁇ -casein
  • lane 5 induced HMS174 (DE3)pLysS (pET-lld-CKII ⁇ )
  • lane 6 induced HMS174 (DE3)pLysS (pRJB-9)
  • lane 7 induced HMS174 (DE3)pLysS (pRJB-9)
  • HMS174 (DE3)pLysS (pS637) ,- lane 10: 1 ⁇ g recombinant human ⁇ -casein; lane 11: 2 ⁇ g recombinant human ⁇ -casein.
  • Figure 10 shows an immunoblot analysis using antibody to human ⁇ -casein.
  • Lane 1 molecular weight marker (Gibco BRL, relative molecular weights 44, 28.9,
  • lane 2 native human ⁇ -casein
  • lane 3 induced HMS174 (DE3 )pLysS (pRJB-9)
  • lane 4 induced HMS174 (DE3 )pLysS (pS637)
  • lane 5 induced HMS174 (DE3 )pLysS (pS637)
  • HMS174 (DE3)pLysS (pET-lld-CKII ⁇ ) ; lane 6: recombinant human ⁇ -casein.
  • Figure 11 shows an immunoblot analysis using antibody to phosphoserine.
  • Lane 1 molecular weight marker (Gibco BRL, relative molecular weights 44, 28.9, 18.5, 14.7, 5.8, 2.9 kDa) ;
  • lane 2 1 ⁇ g native human ⁇ - casein;
  • lane 3 500 ng native human ⁇ -casein;
  • lane 4 induced HMS174 (DE3)pLysS (pRJB-9) ;
  • lane 5 induced HMS174(DE3)pLysS(pS637) ;
  • lane 6 induced
  • the present invention relates to a method for producing a modified recombinant protein in a host cell.
  • the invention relates to a method for producing a phosphorylated human protein in a bacterial cell.
  • the method comprises the steps of preparing a single vector having both a nucleotide sequence encoding an exogenous protein that is capable of being phosphorylated by a protein kinase and a nucleotide sequence encoding an appropriate protein kinase, expressing the vector in a host cell whereby the produced kinase phosphorylates the produced exogenous protein, and isolating the phosphorylated recombinant protein.
  • the present invention provides the unexpected discovery that placing the nucleotide sequence encoding the protein to be phosphorylated and the nucleotide sequence encoding the kinase in tandem in a single construct with a promoter results in high level and specific phosphorylation while eliminating the negative features associated with multiple vectors such as the need for antibiotic resistance genes to be used as markers.
  • Use of the single construct system facilitates scaling up the procedure for industrial use. It is contemplated that the method of the invention will be useful in any host cell system that is capable of expressing the exogenous protein. Suitable host cells include both prokaryotes such as bacteria and eukaryotes such as yeast and animal cells. In the preferred embodiment of the present invention the host cell is E. coli .
  • Nucleotide sequences encoding ⁇ —casein in several different expression formats, were evaluated for expression of recombinant human ⁇ -casein in an E. coli strain. After a series of experiments, it was determined that recombinant human ⁇ -casein was efficiently phosphorylated when sequences encoding human ⁇ —casein were placed in a single construct with sequences encoding human casein kinase CKII ⁇ . Efficiency of phosphorylation was not compromised when both genes were placed in tandem in one plasmid when compared with experimental systems in which sequences encoding the kinase and the ⁇ -casein were placed in two separate vectors.
  • Plasmid construct pS637 shown in Figure 1 is identical to pS26, constructed and described in Hansson et al. , (1993) , which is herein incorporated by reference, except that it encodes an additional amino acid, glutamine (Gin), at position 19.
  • the original expression vector, pS26 was modified to create pS637 which produces a recombinant ⁇ -casein protein identical to the most abundant variant found in human populations.
  • the construct pS637 was prepared for co-expression with the nucleotide sequence encoding casein kinase II (Shi et al . , 1994), which is hereby incorporated by reference, by placing the nucleotide sequence encoding
  • CKII ⁇ which codes for two casein kinase subunits, ⁇ and ⁇ , as a cassette, downstream from the nucleotide sequence encoding ⁇ -casein.
  • a three-cistron tandem expression vector pET-lld-CKII ⁇ is a plasmid containing CKII ⁇ that was generated by Shi et al. (1994) .
  • pS637 was cut at two sites downstream of the ⁇ -casein encoding sequence and religated.
  • a plasmid, pRJB-6, shown in Figure 1 was isolated which had lost 191 bases between the two cut sites.
  • the kinase CKII ⁇ was prepared for insertion into pRJB-6.
  • pRJB-9 is a single construct designed to mediate production of phosphorylated ⁇ -casein.
  • pS637 was also modified to construct the plasmids pS750 and pRJB-7 which will be described in further detail below.
  • the host organism transformed by the described vectors was E. coli .
  • Other representative organisms that could be used with the method of the invention include Bacillus, Lactohacillus, and Streptococcus species.
  • T7 promoter was used.
  • Other representative promoters that could be used with the method of the invention include the inducible promoters ⁇ P L and ⁇ P R and Tac and the constitutive promoters hla and spa .
  • Expression vector pS637 differs from pS26, described in Hansson et al. (1993) as it contains a nucleotide triplet encoding the glutamine (Gin) amino acid residue at position 19 of the ⁇ -casein encoding sequence.
  • This nucleotide sequence was isolated from a human cDNA variant that is more commonly found in human populations than is the sequence of pS26.
  • Two synthetic oligonucleotides were synthesized for poly erase chain reaction (PCR) amplification. The synthetic oligonucleotides provide convenient restriction sites and incorporated codons for amino acids used preferentially by bacteria. The two oligonucleotides were designated SYM4174 (Seq.ID NO: 1) and SYM4175 (Seq.ID NO: 2) and have the following sequences:
  • the 85 bp Pstl/Avall digested PCR-amplified fragment and the 197 bp Avail /AccI were ligated into Pstl /AccI digested pS25, a plasmid described in Hansson et al .
  • the resulting plasmid construct was sequenced and designated pS636.
  • a 644 bp Ndel and BarnHI restriction fragment was isolated from pS636 and introduced into Ndel /BamHI digested vector pS26, a plasmid described in Hansson et al .
  • the resulting expression vector was designated pS637.
  • the pET-lld-CKII ⁇ plasmid comprising the CKII ⁇ encoding sequences generated by Shi et al. (1994) was prepared for co-expression with recombinant ⁇ -casein.
  • Clal cut CKII ⁇ encoding sequence was inserted into pRJB-6, downstream from the ⁇ -casein encoding sequence, and the resulting construct was designated pRJB-9 and is shown in Figure 2.
  • the construct pS637 was prepared for co-expression of recombinant ⁇ -casein and the CKII ⁇ kinase by placing the CKII ⁇ encoding sequence immediately after the ⁇ -casein encoding sequence.
  • the CKII ⁇ encoding sequence was placed as a Bglll/BamH I fragment into the BamH I site of pS637 and designated pRJB-7.
  • This fragment contained the T7 promoter from its original vector, pET-HD-CKII ⁇ .
  • pRJB-7 contains two T7 promoters, one before the ⁇ - casein encoding sequence and one before the CKII ⁇ encoding sequence.
  • the plasmid pS637 was digested with Pvul and treated with T4 DNA polymerase to generate blunt ends.
  • the linearized vector was isolated and ligated with a Hindi kanamycin resistance genblock (Pharmacia, Uppsala, Sweden) .
  • the resulting expression vector was designated pS750 ( Figure 4) .
  • the medium was supplemented with 30 ⁇ g/ml chloramphenicol when the strains containing the pLys plasmids, which confer resistance to chloramphenicol, were used.
  • the cells were harvested about 90 minutes after induction.
  • Electrophoresis and Detection of Recombinant ⁇ -Casein Cells were pelleted by centrifugation and the pellet from 1 ml of culture was dissolved in 100 ⁇ l of sample buffer, which contains Tris, glycerol, SDS, dithiothreotol (DTT) , and bromophenol blue.
  • sample buffer which contains Tris, glycerol, SDS, dithiothreotol (DTT) , and bromophenol blue.
  • the proteins were separated by SDS-PAGE as described in Laemmli (Nature 227:680-685, 1970) .
  • Gradient gels were cast and run in the discontinuous buffer system in a Protean (Bio-Rad, Richmond, CA) electrophoresis unit. Gels were stained as described in Laemmli. Immunoblotting was performed according to the specifications of the manufacturer (Bio-Rad) .
  • the modified protein can be isolated by any standard procedure known to those skilled in the art. Representative of such standard procedures is the following:
  • Cells are harvested and ruptured by standard mechanical or chemical procedures. Cells are then suspended in buffer, homogenized and centrifuged and the supernatant is discarded. The resulting insoluble pellet is resuspended and the supernatant is discarded. This results in a washed insoluble pellet that is suspended in 50 mM Tris and 6 M Urea at pH 8.2 and homogenized, ⁇ —casein supernatant I is removed resulting in an insoluble extract that is again suspended in 50 mM Tris and 6 M Urea at pH 8.2 and homogenized. ⁇ -casein supernatant II is removed and supernatant ⁇ I and II are pooled. The remaining insoluble extract is discarded.
  • the pooled supernatants are diluted 1:1 with 50 mM Tris and pH 8.2 and treated with 3 M Urea to extract ⁇ - casein.
  • the final ⁇ -casein solution is obtained by dialyzing the Urea extract of ⁇ -casein against 50 mM ethanolamine and 100 mM NaCl at pH 9.5, centrifuging, and diluting in 50 mM ethanolamine, 100 mM NaCl at pH 9.5 to a protein concentration of 5 mg/ml. The pellet is discarded.
  • Example 4 describes a system in which a single construct, containing a promoter and both the nucleotide sequence coding for the protein to be transcribed and phosphorylated and the nucleotide sequence coding for the kinase, was used to transform a bacterial strain.
  • a single construct containing a promoter and both the nucleotide sequence coding for the protein to be transcribed and phosphorylated and the nucleotide sequence coding for the kinase, was used to transform a bacterial strain.
  • Example 4 production of recombinant phosphorylated ⁇ -casein using a single plasmid was demonstrated.
  • a single construct system for expression of extracellularly localized recombinant phosphorylated ⁇ - casein that is identical to human native ⁇ -casein is described in Example 5.
  • Example 6 shows a comparison of six phosphoforms of native human and recombinant human ⁇ -caseins made under the direction of the plasmid of the invention in their ability to inhibit adhesion of the bacterium H. influenzae to human pharyngeal cells.
  • DE3 is a DNA fragment derived from a lambda phage containing a lacl repressor, a __acUV5 promoter which is inducible by isopropyl ⁇ —D-thiogalactopyranoside (IPTG), and a gene for T7 RNA polymerase. In the presence of the inducer, T7 RNA polymerase is produced resulting in transcription of the exogenous genes.
  • Plasmid pLysS confers resistance to chloramphenicol and has little effect on growth rate and production of foreign protein. It contains a T7 lysozyme that increases stability of plasmids in E. coli and permits the cells to be lysed by freezing and thawing.
  • Results as seen in Figure 5 indicate that high levels of recombinant human Met- ⁇ -casein were produced in E. coli and that the amount produced was not influenced by co-production of recombinant human CKII ⁇ . After electrophoretic separation of the proteins and phosphate staining, CKII ⁇ is seen to have phosphorylated recombinant human Met- ⁇ -casein in vivo .
  • Example 2 Production of ⁇ -casein in E.coli K-12: Phosphor y lation of intracellularlv localized recombinant Met- ⁇ -casein: HMS174 (DE3) strains
  • HMS174(DE3), HMS174 (DE3JpLysS, and HMS 174 (DE3)pLysE were evaluated as hosts for production of recombinant human Met- ⁇ -casein and were transformed with pS750. The most efficient production was achieved with HMS174 (DE3)pLysS.
  • Co-expression experiments using pS750 and pET-lld-CKII ⁇ showed strong induction of recombinant human Met- ⁇ -casein production, which was independent of the presence of pET-lld-CKII ⁇ .
  • Phosphate staining ( Figure 7) showed efficient phosphorylation of Met- ⁇ - casein when co-produced in vivo with recombinant human CKII.
  • a two plasmid system is inherently less desirable than the single plasmid system of the present invention as each of the plasmids must contain an antibiotic marker so that its presence in the host cells can be monitored during the fermentation process. This necessitates the use of two antibiotics in the growth medium and retards bacterial growth.
  • Example 3 Production of human ⁇ -casein E. coli K-12:
  • Figure 8 shows an immunoblot in which production of ⁇ -casein by E. coli HMS174(DE3)LysS cells containing four different constructs is compared. Lysates from both induced and uninduced cell cultures are analyzed. Cells contain pET-lld-CKII ⁇ (plasmid with CKII ⁇ and CKII ⁇ encoding sequences) , pRJB-9 (hybrid construct with both CKII ⁇ -casein and CKII CKII ⁇ encoding sequences and
  • T7 promoter in front of ⁇ -casein encoding sequence only or pRJB-7 (hybrid construct with both ⁇ -casein and CKII ⁇ encoding sequences and T7 promoters in front of both ⁇ -casein and CKII ⁇ encoding sequences) . Transformation of the bacteria with pRJB-7 resulted in severe reduction of bacterial growth. E. coli HMS174 (DE3)LysS had approximately twice the doubling time as did the same strain transformed with pRJB-9, the construct with only one T7 promoter.
  • the Western blot shown in Figure 8 shows reduced production of recombinant CKII ⁇ -casein by induced cells containing pRJB-7 when compared with cells containing pRJB-9. This is seen by comparing lane 4 (induced pRJB-7) with lane 8 (induced pRJB-9) . Although both pRJB-7 and pRJB-9 are derived from pS637, only pRJB-9 produced amounts of CKII ⁇ -casein equivalent to the parent construct. The presence of an additional T7 promoter before the CKII genes in the hybrid construct had the effect of both reducing cell growth and consequently reducing recombinant protein production.
  • Figure 9 shows a Western blot analysis in which the lysates were developed with phosphoserine antibody to detect phosphorylated protein. Induced E. coli
  • HMS174 (DE3)LysS cells containing pET-lld- CKII ⁇ , pRJB-9 (hybrid construct with one T7 promoter) , pRJB-7 (hybrid construct with two T7 promoters) , or pS637 (contains ⁇ -casein encoding sequence but not CKII ⁇ encoding sequence) were compared for production of phosphorylated recombinant ⁇ -casein. Phosphorylated ⁇ - casein was produced only in cells containing pRJB-9 (lane 6) . No phosphorylated protein was detected in lane 7, which contains the lysate of cells containing pRJB-7.
  • Example 4 Production of human ⁇ -casein in E. coli K-12: Construct pRJB-9 containing both ⁇ -casein encoding sequence and CKII ⁇ encoding sequences
  • the present invention uses a single construct expressing both the information for transferring functional groups to specific sites and the protein to be modified.
  • the transferred functional group is phosphate.
  • the transfer is accomplished by a kinase that is demonstrated to mediate phosphorylation of specific sites on recombinant human ⁇ -casein in vivo .
  • This invention demonstrates that not only can human ⁇ —casein be specifically phosphorylated in vivo by E. coli , but that a single-construct with a promoter located before the sequence encoding ⁇ -casein and having the advantages of a single-construct system can successfully mediate this function.
  • HMS174 (DE3)LysS.
  • the transformation procedure followed was that of the Novagen pET system manual (4th ed. , TB No.55, June, 1994) .
  • Culture samples were taken before and 6 hours after adding 1 mM of the inducer IPTG. Cells from two 1 ml aliquots were pelleted by centrifugation in a microcentrifuge. Cells were resuspended in sample loading buffer for gel electrophoresis after which 500 ⁇ l of the supernatants from each aliquot were collected.
  • the spent culture medium was concentrated in a Microcon 10 spin filter (Amicon) for 35 minutes at 10,000 x G. The retentate was collected after spinning for 3 minutes at 1,000 x G and an equal amount of sample buffer at double concentration was added.
  • FIG. 10 shows an immunoblot in which production of ⁇ -casein by E. coli K-12 HMS174 (DE3)LysS cells containing three different constructs is compared.
  • Cells contain pS637 (plasmid with ⁇ -casein encoding sequence) , pET-lld- CKII ⁇ (plasmid with CKII ⁇ and ⁇ encoding sequences) , or pRJB-9 (hybrid construct with both ⁇ —casein and CKII ⁇ encoding sequences) .
  • Comparison of lanes 3 and 4 shows that the hybrid construct, pRJB-9, is producing equivalent amounts of ⁇ - casein to pS637, from which it was derived and which does not contain the CKII ⁇ encoding sequences. Both pRJB-9 and pS637 produced between 400-500 mg/L of ⁇ - casein in this host cell. This experiment shows that placing the ⁇ -casein encoding sequence in tandem with the encoding sequence for CKII ⁇ does not significantly change production of ⁇ -casein.
  • Figure 11 shows a Western blot analysis in which the lysates were developed with phosphoserine antibody to detect phosphorylated protein.
  • E. coli K-12 in a bacterial system using a single construct E. coli K-12 in a bacterial system using a single construct.
  • Example 5 Production of ⁇ -casein in E.coli K-12: Phosphorylation of extracellularlv localized recombinant ⁇ -casein: Construct containing E. coli leader sequence, promoter, ⁇ -casein encoding sequence.
  • pET-lld-CKII ⁇
  • the construction of a single plasmid that is used to transform E. coli K-12 and mediate production of extracellularly localized phosphorylated ⁇ -casein is disclosed.
  • the ⁇ -casein encoding sequence is put into an expression vector containing a leader sequence that directs protein transport to the periplasm.
  • PCR polymerase chain reaction
  • the following primers synthesized at Midland Certified Reagent Co. (Midland, TX) . can be used in the PCR, RO-4: 5 ' -TGT AAA ACG GCC ACT-3 ' (Seq.ID No: 3) and RO-29: 5 ' -GGG GAT CCG TAC GCG TGA AAC-3 ' (Seq.ID No: 4)
  • the base underlined in RO-29 incorporates a single base change to create an Mlul site at the end of the ⁇ -casein encoding sequence in order to eliminate the bacterial initiation codon, methionine, for protein synthesis. This is done so that the resulting protein will have an amino acid sequence identical to that of human ⁇ -casein.
  • the PCR fragment is then purified.
  • the 3' end of the encoding sequence, which is not modified, is cut with BamH I.
  • This fragment containing a 5 1 blunt end and 3 1 Ba H I end, is cloned in the expression vector pET-26b (Novagen, Madison, WI) , which contains a T7 promoter, and cut at the blunt end with MscI and with BamH I.
  • the construct described here contains the T7 promoter, but other promoter sequences could be used.
  • the CKII ⁇ encoding sequence is inserted as described above for pRJB-9. Expression is induced and Western blot analysis is performed according to the procedures described in Example 4.
  • a Western blot is performed to identify a protein, isolated from the periplasmic space of the bacterial cells, that cross-reacts with antibody to phosphoserine and migrates similarly to native ⁇ -casein.
  • This experiment demonstrates phosphorylation of recombinant human ⁇ -casein encoded by a sequence fused to a heterologous translational start and signal sequence, this sequence being preceded by a promoter sequence, and the sequence to be phosphorylated being located in a plasmid containing a kinase encoding sequence such as CKII ⁇ . Production of extracellularly localized phosphorylated protein has not been previously disclosed either in a one-vector or a two-vector system.
  • the advantage of extracellular over intracellular localization of the produced phosphorylated protein lies in the ease of its purification.
  • the periplasmic space of bacterial cells contains less extraneous matter than the interior of the cell so that isolation of the purified protein is expedited. This is particularly advantageous during commercial production.
  • Haemophilus are small, gram-negative bacilli with a lipopolysaccharide-protein cell wall and are obligate parasites present on the mucous membranes of humans and animal species.
  • the surface of many but not all strains of Haemophilus influenzae is covered with a polysaccharide capsule.
  • Nonencapsulated, nontypeable H. influenzae strains colonize the upper respiratory tract in most individuals within the first few months of life and is the species most commonly associated with several diseases including otitis media and sinusitis (Murray et al., Medical Microbiology, 2d ed. , p.260, 1994) . They can also exacerbate chronic bronchitis.
  • Detroit 562 human pharynx carcinoma cells were obtained from the American Type Culture Collection (Rockville, MD) .
  • the H. influenzae nontypeable bacterial strain was obtained from Dr. Lauren Bakaletz at the Ohio State University.
  • HBSS Balanced Salt Solution
  • H. influenzae were streaked onto chocolate agar plates from frozen aliquots of a low passage number and incubated at 37 "C in a humidified atmosphere of 95% air and 5% carbon dioxide for 18 hours to obtain log phase cultures.
  • Bacteria harvested in phosphate buffered saline (PBS) supplemented with 0.05% bovine serum albumin ( (BSA) were centrifuged and resuspended in a volume of PBS/BSA yielding an optical density of 2.4 at a wave length of 600 nm (OD 60 o) • 1:L1 Indium-oxine (min) (Amersham, Arlington Heights, IL) was used to radiolabel the bacteria.
  • PBS phosphate buffered saline
  • BSA bovine serum albumin
  • Results were calculated by averaging the results of four replicates. Results are presented as the percent inhibition of bacterial adhesion with native human or recombinant (pRJB-9) ⁇ -casein at 6 different phosphorylation levels when compared to bacterial attachment in control wells containing no test agent.
  • Anti-adhesion activity is only seen consistently when ⁇ -casein is phosphorylated with 3, 4, or 5 phosphate groups. At lower levels of phosphorylation little or no anti-adhesion was observed with either native or recombinant ⁇ —casein. However, at higher phosphoforms when ⁇ -casein had 3, 4, or 5 phosphates there was essentially no difference between the anti-adhesion bioactivity of native or recombinant
  • H. influenzae has been identified as a causative factor for otitis media (Murray et al . , 1994) . Since it has been demonstrated in the experiments described above that recombinant human ⁇ -casein phosphorylated in at least three sites under the direction of the plasmid of the invention inhibits adhesion of H. influenzae to human cells, it is concluded that phosphorylated recombinant human ⁇ -casein, as described above, may be used in the prevention and treatment of otitis media in humans, particularly in human infants.
  • Therapeutic effects may be provided by enterally feeding or ingesting an enteral liquid nutritional product, such as infant formula, comprising a therapeutically effective amount of the phosphorylated recombinant human ⁇ -casein with 3 or more phosphate groups disclosed herein.
  • the attachment of H. influenzae to human oropharyngeal cells may also be inhibited by administering via a nasal passageway, or as a throat spray, a formulation containing a therapeutically effective amount of phosphorylated recombinant human ⁇ -casein.
  • a nasally administered formulation may be in the form of either drops or a spray.
  • Administration of enteral, throat spray and nasal products is believed to be effective because the interaction of human ⁇ —casein is believed to occur by direct contact in the nasopharynx rather than after ingestion and digestion of the ⁇ -casein.
  • This invention will allow commercial-scale production of phosphorylated, recombinant mammalian proteins in microorganisms.
  • the method of the invention can be used to produce recombinant exogenous proteins, including but not limited to, recombinant human ⁇ — casein, in large quantities.
  • Phosphorylation of ⁇ - casein in a bioreactor makes possible large-scale synthesis in a fermentor of recombinant ⁇ -casein that is equivalent to native human ⁇ -casein. This will facilitate the production of infant formula containing human ⁇ -casein in its native phosphorylated state.
  • the method of the invention can also be used for phosphorylation of cell proteins, including receptors which are regulated by phosphorylation and dephosphorylation and thereby act as signals in cell metabolism.
  • the invention provides a cost-effective method of phosphorylating peptide receptors and will be useful in the manufacture of pharmaceutical drugs.
  • the single plasmid system is preferable to a two-plasmid system for industrial production of fermented proteins such as recombinant, phosphorylated human ⁇ —casein.
  • Phosphorylated recombinant human ⁇ -casein with 3 to 5 phosphate groups can be incorporated into any standard or specialized enteral liquid nutritional product including but not limited to infant formulas containing protein from non-human mammalian milk such as bovine or goat milk or protein from vegetable sources such as soybeans or rice, as well as other beverages consumed by young children.
  • a product incorporating phosphorylated recombinant human ⁇ -casein having 3 to 5 phosphate groups has utility for the inhibition of attachment of H. influenzae to human cells and the treatment and prevention of otitis media in human infants.
  • the discovery disclosed herein of a novel method for producing recombinant, phosphorylated human ⁇ - casein, with characteristics similar or identical to that of native human ⁇ -casein, makes feasible the addition of this protein to infant formula so as to render it more similar to human milk with consequential benefits to developing infants.
  • the disclosure of a method for producing recombinant, modified human proteins in a bacterial system also makes feasible the addition of the human proteins to other food and pharmaceutical products.
  • MOLECULE TYPE genomic DNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention décrit un plasmide contenant une séquence de promoteurs, une séquence nucléotidique codant une protéine exogène et une séquence nucléotidique codant un enzyme capable de modifier cette protéine exogène. Dans un mode de réalisation spécifique, la protéine exogène codée est la caséine β humaine et l'enzyme codé est une kinase humaine capable de réaliser la phosphorylation de la caséine β de recombinaison dans un système bactérien.
PCT/US1996/002866 1995-02-27 1996-02-27 Plasmide pour l'expression de proteines de recombinaison modifiees dans un systeme bacterien WO1996027018A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
NZ303621A NZ303621A (en) 1995-02-27 1996-02-27 A plasmid contains recombinant proteins such as human beta-casein with an encoded exogenous enzyme such as human kinase capable of phosphorylating recombinant beta-casein in a bacterial system
JP8526438A JPH11500920A (ja) 1995-02-27 1996-02-27 修飾された組換えタンパク質を細菌系において発現させるプラスミド
EP96906664A EP0812362A1 (fr) 1995-02-27 1996-02-27 Plasmide pour l'expression de proteines de recombinaison modifiees dans un systeme bacterien

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US39523995A 1995-02-27 1995-02-27
US08/395,239 1995-02-27
US08/554,137 US5942254A (en) 1995-02-27 1995-11-06 Phosphorylated recombinant human β-casein expressed in a bacterial system
US08/554,642 US5710044A (en) 1995-02-27 1995-11-06 Plasmid for expressing phosphorylated recombinant proteins in a bacterial system
US08/554,642 1995-11-06
US08/554,137 1995-11-06

Publications (1)

Publication Number Publication Date
WO1996027018A1 true WO1996027018A1 (fr) 1996-09-06

Family

ID=27410154

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/002866 WO1996027018A1 (fr) 1995-02-27 1996-02-27 Plasmide pour l'expression de proteines de recombinaison modifiees dans un systeme bacterien

Country Status (5)

Country Link
EP (1) EP0812362A1 (fr)
JP (1) JPH11500920A (fr)
CA (1) CA2213734A1 (fr)
NZ (1) NZ303621A (fr)
WO (1) WO1996027018A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017085A2 (fr) * 1995-11-06 1997-05-15 Abbott Laboratories Procede permettant d'inhiber la fixation de h. influenzae sur des cellules humaines a l'aide de beta-caseine humaine phosphorylee de recombinaison
WO1997026320A2 (fr) * 1995-11-06 1997-07-24 Abbott Laboratories Produit servant a inhiber la fixation de h. influenzae sur des cellules humaines
US5707968A (en) * 1994-05-26 1998-01-13 Abbott Laboratories Inhibition of attachment of H.influenzae to human cells
US5942254A (en) * 1995-02-27 1999-08-24 Abbott Laboratories Phosphorylated recombinant human β-casein expressed in a bacterial system
WO2000008174A1 (fr) * 1998-08-07 2000-02-17 Abbott Laboratories Produits de synthese exprimant la beta-caseine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0178863A1 (fr) * 1984-10-15 1986-04-23 Schering Corporation Systèmes d'expression utilisant des promoteurs de bactériophage T7 et des séquences de gènes
EP0445097A2 (fr) * 1990-02-26 1991-09-04 Washington University Méthode de protéine N-myristoylation
WO1992009698A1 (fr) * 1990-11-26 1992-06-11 Genetics Institute, Inc. Expression de pace dans des cellules hotes et procedes d'utilisation
EP0548012A1 (fr) * 1991-12-16 1993-06-23 Ciba-Geigy Ag Endoprotéase dibasique recombinante localisée dans le réticulum endoplasmique et ses applications
WO1994013796A1 (fr) * 1992-12-14 1994-06-23 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Clonage d'expression d'une phosphatase humaine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0178863A1 (fr) * 1984-10-15 1986-04-23 Schering Corporation Systèmes d'expression utilisant des promoteurs de bactériophage T7 et des séquences de gènes
EP0445097A2 (fr) * 1990-02-26 1991-09-04 Washington University Méthode de protéine N-myristoylation
WO1992009698A1 (fr) * 1990-11-26 1992-06-11 Genetics Institute, Inc. Expression de pace dans des cellules hotes et procedes d'utilisation
EP0548012A1 (fr) * 1991-12-16 1993-06-23 Ciba-Geigy Ag Endoprotéase dibasique recombinante localisée dans le réticulum endoplasmique et ses applications
WO1994013796A1 (fr) * 1992-12-14 1994-06-23 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Clonage d'expression d'une phosphatase humaine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 112, no. 19, 7 May 1990, Columbus, Ohio, US; abstract no. 173552r, JIMENEZ-FLORES, R. ET AL.: "Expression of bovine beta-casein in Saccharomyces cerevisiae and characterization of the protein produced in vivo." page 221; XP002006869 *
CHEMICAL ABSTRACTS, vol. 120, no. 3, 17 January 1994, Columbus, Ohio, US; abstract no. 25819, HANSSON, LENNART ET AL: "Expression of human milk.beta.- casein in Escherichia coli: Comparison of recombinant protein with native isoforms" XP002006870 *
J.AGRIC.FOOD CHEM., vol. 38, no. 4, 1990, pages 1134 - 1141 *
JIMENEZ-FLORES, R. ET AL.: "Genetic engineering of the caseins to modify the behavior of milk during processing:A review", JOURNAL OF DAIRY SCIENCE, vol. 71, no. 10, 1988, CHAPAIGN, ILLINOIS US, pages 2640 - 2654, XP002006868 *
PROTEIN EXPRESSION PURIF. (1993), 4(5), 373-81 CODEN: PEXPEJ;ISSN: 1046-5928 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707968A (en) * 1994-05-26 1998-01-13 Abbott Laboratories Inhibition of attachment of H.influenzae to human cells
US5942254A (en) * 1995-02-27 1999-08-24 Abbott Laboratories Phosphorylated recombinant human β-casein expressed in a bacterial system
WO1997017085A2 (fr) * 1995-11-06 1997-05-15 Abbott Laboratories Procede permettant d'inhiber la fixation de h. influenzae sur des cellules humaines a l'aide de beta-caseine humaine phosphorylee de recombinaison
WO1997026320A2 (fr) * 1995-11-06 1997-07-24 Abbott Laboratories Produit servant a inhiber la fixation de h. influenzae sur des cellules humaines
WO1997017085A3 (fr) * 1995-11-06 1997-08-07 Abbott Lab Procede permettant d'inhiber la fixation de h. influenzae sur des cellules humaines a l'aide de beta-caseine humaine phosphorylee de recombinaison
WO1997026320A3 (fr) * 1995-11-06 1997-09-12 Abbott Lab Produit servant a inhiber la fixation de h. influenzae sur des cellules humaines
US6287866B1 (en) 1996-11-27 2001-09-11 Abbott Laboratories β-casein expressing constructs
WO2000008174A1 (fr) * 1998-08-07 2000-02-17 Abbott Laboratories Produits de synthese exprimant la beta-caseine

Also Published As

Publication number Publication date
CA2213734A1 (fr) 1996-09-06
JPH11500920A (ja) 1999-01-26
NZ303621A (en) 1999-04-29
EP0812362A1 (fr) 1997-12-17

Similar Documents

Publication Publication Date Title
CA2015994C (fr) Sequence d'adn-c de lactoferrine humaine
Debabov et al. The D-alanyl carrier protein in Lactobacillus casei: cloning, sequencing, and expression of dltC
Koke et al. High-level expression in Escherichia coli and rapid purification of phosphatidylinositol-specific phospholipase C from Bacillus cereus and Bacillus thuringiensis
Alpert et al. Molecular cloning and DNA sequence of lacE, the gene encoding the lactose-specific enzyme II of the phosphotransferase system of Lactobacillus casei. Evidence that a cysteine residue is essential for sugar phosphorylation.
Oudega et al. Protein H encoded by plasmid CloDF13 is involved in excretion of cloacin DF13
US5807702A (en) Method for expressing phosphorylated recombinant human β-casein in a bacterial system
EP0812362A1 (fr) Plasmide pour l'expression de proteines de recombinaison modifiees dans un systeme bacterien
Kim et al. Purification, reconstitution, and characterization of Na+/serine symporter, SstT, of Escherichia coli
US5710044A (en) Plasmid for expressing phosphorylated recombinant proteins in a bacterial system
WO1997017085A9 (fr) Procede permettant d'inhiber la fixation de h. influenzae sur des cellules humaines a l'aide de beta-caseine humaine phosphorylee de recombinaison
WO1997017085A2 (fr) Procede permettant d'inhiber la fixation de h. influenzae sur des cellules humaines a l'aide de beta-caseine humaine phosphorylee de recombinaison
WO1994000463A2 (fr) Production d'acide hyaluronique a l'aide de microorganismes transformes
JP2018514231A (ja) 増殖とタンパク質生成との分離
EP0859629B1 (fr) Beta-caseine humaine recombinante et phosphorylee pour inhiber la fixation de h. influenzae sur des cellules humaines
US5942254A (en) Phosphorylated recombinant human β-casein expressed in a bacterial system
Taylor et al. Bacteriophage λ lysis gene product modified and inserted into Escherichia coli outer membrane: Rz1 lipoprotein
WO1996027017A1 (fr) Methode d'expression de proteines recombinantes modifiees dans un systeme bacterien
KR102633804B1 (ko) 재조합 바실러스 속 미생물 및 이를 이용한 모유올리고당 제조방법
JPH02501976A (ja) ピキア・パストリスからの分泌による動物リゾチームｃの生産とその結果生ずる組成物
CA2234664A1 (fr) Procede permettant d'inhiber la fixation de h. influenzae sur des cellules humaines a l'aide de beta-caseine humaine phosphorylee de recombinaison
JP2003512060A (ja) 膜タンパク質のための発現系
CN101775404A (zh) 一种原核表达体系高表达碱性蛋白的方法
HUT52154A (en) Recombinant interleukin-2 hybrid proteins.
EP0506377A2 (fr) Protéine liant le calmodulin
CZ33390U1 (cs) Genový konstrukt pro produkci lipoproteinů a bakteriální display v E. coli, a jeho produkt

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA FI JP NO NZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 303621

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1996906664

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2213734

Country of ref document: CA

Ref country code: CA

Ref document number: 2213734

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 526438

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996906664

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996906664

Country of ref document: EP